NZ604082A - Method for treating multiple sclerosis - Google Patents
Method for treating multiple sclerosisInfo
- Publication number
- NZ604082A NZ604082A NZ604082A NZ60408205A NZ604082A NZ 604082 A NZ604082 A NZ 604082A NZ 604082 A NZ604082 A NZ 604082A NZ 60408205 A NZ60408205 A NZ 60408205A NZ 604082 A NZ604082 A NZ 604082A
- Authority
- NZ
- New Zealand
- Prior art keywords
- antibody
- cdr
- amino acid
- acid sequence
- exposure
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US57699304P | 2004-06-04 | 2004-06-04 | |
NZ59250105 | 2005-06-02 |
Publications (1)
Publication Number | Publication Date |
---|---|
NZ604082A true NZ604082A (en) | 2014-09-26 |
Family
ID=35351693
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NZ604082A NZ604082A (en) | 2004-06-04 | 2005-06-02 | Method for treating multiple sclerosis |
Country Status (20)
Country | Link |
---|---|
US (3) | US20060051345A1 (pt) |
EP (2) | EP3130349A1 (pt) |
JP (1) | JP2008501712A (pt) |
KR (3) | KR20130099228A (pt) |
CN (3) | CN102512675A (pt) |
AR (1) | AR049200A1 (pt) |
AU (1) | AU2005249566B2 (pt) |
BR (1) | BRPI0510915A (pt) |
CA (1) | CA2566979A1 (pt) |
IL (2) | IL179139A (pt) |
MX (1) | MXPA06014069A (pt) |
MY (1) | MY194883A (pt) |
NO (1) | NO20070052L (pt) |
NZ (1) | NZ604082A (pt) |
RU (1) | RU2384345C2 (pt) |
SG (1) | SG183012A1 (pt) |
SV (1) | SV2006002132A (pt) |
TW (2) | TWI433682B (pt) |
WO (1) | WO2005117978A2 (pt) |
ZA (1) | ZA200610158B (pt) |
Families Citing this family (63)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1637160A3 (en) * | 1999-05-07 | 2006-05-03 | Genentech, Inc. | Treatment of autoimmune diseases with antagonists which bind to B cell surface markers |
CN1592645A (zh) * | 2000-09-18 | 2005-03-09 | 拜奥根Idec公司 | 使用b细胞耗尽/免疫调节抗体组合治疗自身免疫病的联合疗法 |
US7754208B2 (en) | 2001-01-17 | 2010-07-13 | Trubion Pharmaceuticals, Inc. | Binding domain-immunoglobulin fusion proteins |
ES2633311T3 (es) * | 2002-12-16 | 2017-09-20 | Genentech, Inc. | Variantes de inmunoglobulina y usos de las mismas |
ME03330B (me) | 2003-11-05 | 2019-10-20 | Roche Glycart Ag | Cd20 antitijela sa povećanim afinitetom za vezivanje fc receptora i efektornom funkcijom |
WO2005090405A1 (ja) | 2004-03-24 | 2005-09-29 | Chugai Seiyaku Kabushiki Kaisha | インターロイキン-6受容体に対するヒト型化抗体のサブタイプ |
US20060188495A1 (en) * | 2005-01-13 | 2006-08-24 | Genentech, Inc. | Treatment method |
DOP2006000029A (es) * | 2005-02-07 | 2006-08-15 | Genentech Inc | Antibody variants and uses thereof. (variantes de un anticuerpo y usos de las mismas) |
KR101914254B1 (ko) | 2005-02-18 | 2018-11-02 | 아브락시스 바이오사이언스, 엘엘씨 | 치료제의 조합 및 투여 방식, 및 조합 요법 |
US20070166388A1 (en) | 2005-02-18 | 2007-07-19 | Desai Neil P | Combinations and modes of administration of therapeutic agents and combination therapy |
US8735394B2 (en) | 2005-02-18 | 2014-05-27 | Abraxis Bioscience, Llc | Combinations and modes of administration of therapeutic agents and combination therapy |
PL1912675T3 (pl) | 2005-07-25 | 2014-10-31 | Emergent Product Dev Seattle | Zmniejszanie liczby komórek B za pomocą cząsteczek wiążących swoistych dla antygenów CD37 i CD20 |
PT2001496T (pt) | 2006-03-15 | 2017-09-08 | The Brigham And Women`S Hospital Inc | Utilização de gelsolina para o diagnóstico e tratamento de doenças inflamatórias |
HUE035980T2 (hu) * | 2006-03-15 | 2018-06-28 | Brigham & Womens Hospital Inc | Gelzolin alkalmazása szklerózis multiplex kezelésére és neurológiai betegségek diagnosztizálására |
CA2645322A1 (en) * | 2006-03-16 | 2007-09-27 | Genentech, Inc. | Methods of treating lupus using cd4 antibodies |
US20080279848A1 (en) * | 2006-03-16 | 2008-11-13 | Genentech, Inc. | Methods of treating lupus using CD4 antibodies |
ES2612383T3 (es) | 2006-07-19 | 2017-05-16 | The Trustees Of The University Of Pennsylvania | WSX-1/IL-27 como una diana para respuestas antiinflamatorias |
CN104586815A (zh) | 2006-12-14 | 2015-05-06 | 阿布拉科斯生物科学有限公司 | 用包含紫杉烷的纳米颗粒基于激素受体状态治疗乳腺癌 |
GB0707208D0 (en) * | 2007-04-13 | 2007-05-23 | Istituto Superiore Di Sanito | Novel disease treatments |
US20090214561A1 (en) * | 2007-09-24 | 2009-08-27 | David Robert Close | Treatment method |
US20090155207A1 (en) * | 2007-11-29 | 2009-06-18 | Hariri Robert J | Use of Immunomodulatory Compounds for the Treatment of Transverse Myelitis, Multiple Sclerosis, and Other Disorders |
FI20075968A0 (fi) * | 2007-12-28 | 2007-12-28 | Licentia Oy | Menetelmä immunomodulaattorihoitojen tehokkuuden tarkkailemiseksi |
PL2708603T3 (pl) | 2008-01-25 | 2017-12-29 | Beth Israel Deaconess Medical Ct Inc | Diagnostyczne i terapeutyczne zastosowania gelsoliny w niewydolności nerek |
WO2009102611A2 (en) * | 2008-02-15 | 2009-08-20 | Bayhill Therapeutics, Inc. | Methods of predicting responsiveness of ms patients to immune-based therapy |
CN102099377A (zh) | 2008-04-11 | 2011-06-15 | 新兴产品开发西雅图有限公司 | Cd37免疫治疗剂及其与双功能化学治疗剂的联合 |
US8314151B2 (en) | 2008-04-29 | 2012-11-20 | Enzo Therapeutics, Inc. | Sphingosine kinase type 1 inhibitors, and processes for using same |
US8372888B2 (en) * | 2008-04-29 | 2013-02-12 | Enzo Therapeutics, Inc. | Sphingosine kinase type 1 inhibitors, compositions and processes for using same |
AR077718A1 (es) * | 2008-07-15 | 2011-09-21 | Genentech Inc | Metodos para tratar enfermedades autoinmunes usando anticuerpos anti cd4. formulacion farmaceutica |
WO2010022398A1 (en) * | 2008-08-22 | 2010-02-25 | Isaac Melamed | Diagnosis and treatment of neuro-inflammatory disorders |
TW201014605A (en) | 2008-09-16 | 2010-04-16 | Genentech Inc | Methods for treating progressive multiple sclerosis |
WO2010075249A2 (en) | 2008-12-22 | 2010-07-01 | Genentech, Inc. | A method for treating rheumatoid arthritis with b-cell antagonists |
AR078161A1 (es) * | 2009-09-11 | 2011-10-19 | Hoffmann La Roche | Formulaciones farmaceuticas muy concentradas de un anticuerpo anti cd20. uso de la formulacion. metodo de tratamiento. |
KR20130009760A (ko) | 2010-02-10 | 2013-01-23 | 이뮤노젠 아이엔씨 | Cd20 항체 및 이의 용도 |
PL2552415T3 (pl) | 2010-03-29 | 2017-03-31 | Abraxis Bioscience, Llc | Sposoby leczenia nowotworu |
MX2012011155A (es) | 2010-03-29 | 2012-12-05 | Abraxis Bioscience Llc | Metodos para mejorar suministros de farmacos y efectividad de agentes terapeuticos. |
BR112012030909A2 (pt) | 2010-06-04 | 2020-08-18 | Abraxis Bioscience, Llc | métodos de tratamento de câncer pancreático |
WO2012154215A1 (en) | 2011-05-04 | 2012-11-15 | Cellular Technology, Ltd. | Cns antigen-specific b cell, t cell and antibody assays and their uses in diagnosis and treatment of multiple sclerosis |
WO2013045488A1 (en) * | 2011-09-26 | 2013-04-04 | Universität Zürich Prorektorat Mnw | Apc-mediated tolerance induction for therapy of multiple sclerosis |
JP2015515456A (ja) * | 2012-03-12 | 2015-05-28 | メディミューン,エルエルシー | 抗cd19抗体による多発性硬化症の治療 |
CN105188751A (zh) * | 2013-03-12 | 2015-12-23 | 泰华制药工业有限公司 | 利妥昔单抗诱导疗法继而醋酸格拉替雷疗法 |
US9636318B2 (en) | 2015-08-31 | 2017-05-02 | Banner Life Sciences Llc | Fumarate ester dosage forms |
US9326947B1 (en) | 2014-02-28 | 2016-05-03 | Banner Life Sciences Llc | Controlled release fumarate esters |
US10098863B2 (en) | 2014-02-28 | 2018-10-16 | Banner Life Sciences Llc | Fumarate esters |
ES2713157T3 (es) | 2014-02-28 | 2019-05-20 | Banner Life Sciences Llc | Cápsulas blandas entéricas de liberación controlada de ésteres de fumarato |
SG11201708846XA (en) * | 2015-04-29 | 2017-11-29 | 7 Hills Interests Llc | Novel compositions and methods for immunotherapies comprising small molecule integrin receptor-ligand agonist adjuvants |
RU2600160C1 (ru) * | 2015-08-07 | 2016-10-20 | Юрий Леонидович Шевченко | Способ лечения рассеянного склероза и других системных аутоиммунных заболеваний |
CN115322188A (zh) | 2015-10-30 | 2022-11-11 | 纽罗克里生物科学有限公司 | Valbenazine盐及其多晶形物 |
CN108925135A (zh) | 2015-12-23 | 2018-11-30 | 纽罗克里生物科学有限公司 | 制备(S)-(2R,3R,11bR)-3-异丁基-9,10-二甲氧基-2,3,4,6,7,11b-六氢-1H-吡啶并[2,1-a]异喹啉-2-基2-氨基-3-甲基丁酸酯二(4-甲基苯磺酸盐)的合成方法 |
WO2018008017A1 (en) * | 2016-07-03 | 2018-01-11 | Hadasit Medical Research Services And Development Ltd. | Circulating micrornas as biomarkers for therapy in neuromyelitis optica (nmo) and multiple sclerosis (ms) |
JP7090151B2 (ja) | 2017-01-27 | 2022-06-23 | ニューロクライン バイオサイエンシーズ,インコーポレイテッド | 特定のvmat2インヒビターを投与するための方法 |
CN110382052A (zh) | 2017-03-26 | 2019-10-25 | Mapi医药公司 | 用于治疗进展型形式的多发性硬化症的格拉替雷储库系统 |
US10660879B2 (en) | 2017-06-23 | 2020-05-26 | Enzo Biochem, Inc. | Sphingosine pathway modulating compounds for the treatment of cancers |
CA3061201A1 (en) | 2017-06-23 | 2018-12-27 | Enzo Biochem, Inc. | Sphingosine pathway modulating compounds for the treatment of cancers |
MX2020002841A (es) | 2017-09-21 | 2020-07-22 | Neurocrine Biosciences Inc | Formulacion de valbenazina de alta dosis y composiciones, metodos y kits relacionados con la misma. |
US10993941B2 (en) | 2017-10-10 | 2021-05-04 | Neurocrine Biosciences, Inc. | Methods for the administration of certain VMAT2 inhibitors |
AU2017435893B2 (en) | 2017-10-10 | 2023-06-29 | Neurocrine Biosciences, Inc | Methods for the administration of certain VMAT2 inhibitors |
RU2721282C2 (ru) * | 2017-11-21 | 2020-05-18 | Илья Владимирович Духовлинов | Способ лечения рассеянного склероза (варианты) |
WO2019133890A1 (en) * | 2017-12-29 | 2019-07-04 | University Of Kansas | Nanoparticles including a glatiramoid useful in polynucleotide delivery |
WO2020037022A1 (en) | 2018-08-15 | 2020-02-20 | Neurocrine Biosciences, Inc. | Methods for the administration of certain vmat2 inhibitors |
US20200165608A1 (en) * | 2018-11-23 | 2020-05-28 | Florida State University Research Foundation, Inc. | Inhibition of vascular endothelial cell-mediated phagocytic processes for treatment of demyelinating conditions |
US10940141B1 (en) | 2019-08-23 | 2021-03-09 | Neurocrine Biosciences, Inc. | Methods for the administration of certain VMAT2 inhibitors |
WO2021142062A1 (en) | 2020-01-10 | 2021-07-15 | Banner Life Sciences Llc | Fumarate ester dosage forms with enhanced gastrointestinal tolerability |
JP2023537751A (ja) * | 2020-08-14 | 2023-09-05 | エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト | オクレリズマブで多発性硬化症を治療するための方法 |
Family Cites Families (160)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
IL47062A (en) | 1975-04-10 | 1979-07-25 | Yeda Res & Dev | Process for diminishing antigenicity of tissues to be usedas transplants by treatment with glutaraldehyde |
FR2413974A1 (fr) | 1978-01-06 | 1979-08-03 | David Bernard | Sechoir pour feuilles imprimees par serigraphie |
US4665077A (en) | 1979-03-19 | 1987-05-12 | The Upjohn Company | Method for treating rejection of organ or skin grafts with 6-aryl pyrimidine compounds |
WO1981001145A1 (en) | 1979-10-18 | 1981-04-30 | Univ Illinois | Hydrolytic enzyme-activatible pro-drugs |
US4485045A (en) | 1981-07-06 | 1984-11-27 | Research Corporation | Synthetic phosphatidyl cholines useful in forming liposomes |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US4544545A (en) | 1983-06-20 | 1985-10-01 | Trustees University Of Massachusetts | Liposomes containing modified cholesterol for organ targeting |
US4690905A (en) * | 1983-11-16 | 1987-09-01 | Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva University | Method for removal of human antibodies to native DNA from serum |
US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
US5567610A (en) | 1986-09-04 | 1996-10-22 | Bioinvent International Ab | Method of producing human monoclonal antibodies and kit therefor |
US6893625B1 (en) * | 1986-10-27 | 2005-05-17 | Royalty Pharma Finance Trust | Chimeric antibody with specificity to human B cell surface antigen |
IL85035A0 (en) * | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
GB8705477D0 (en) | 1987-03-09 | 1987-04-15 | Carlton Med Prod | Drug delivery systems |
US4975278A (en) | 1988-02-26 | 1990-12-04 | Bristol-Myers Company | Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells |
US5283187A (en) | 1987-11-17 | 1994-02-01 | Brown University Research Foundation | Cell culture-containing tubular capsule produced by co-extrusion |
US4892538A (en) | 1987-11-17 | 1990-01-09 | Brown University Research Foundation | In vivo delivery of neurotransmitters by implanted, encapsulated cells |
US5506126A (en) | 1988-02-25 | 1996-04-09 | The General Hospital Corporation | Rapid immunoselection cloning method |
HUT53672A (en) | 1988-02-25 | 1990-11-28 | Gen Hospital Corp | Quick immunoselective cloning process |
IL85746A (en) | 1988-03-15 | 1994-05-30 | Yeda Res & Dev | Preparations comprising t-lymphocyte cells treated with 8-methoxypsoralen or cell membranes separated therefrom for preventing or treating autoimmune diseases |
US4861579A (en) | 1988-03-17 | 1989-08-29 | American Cyanamid Company | Suppression of B-lymphocytes in mammals by administration of anti-B-lymphocyte antibodies |
FI891226A (fi) | 1988-04-28 | 1989-10-29 | Univ Leland Stanford Junior | Reseptordeterminanter i anti-t-celler foer behandling av autoimmunsjukdom. |
GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
US5175384A (en) | 1988-12-05 | 1992-12-29 | Genpharm International | Transgenic mice depleted in mature t-cells and methods for making transgenic mice |
WO1990008187A1 (en) | 1989-01-19 | 1990-07-26 | Dana Farber Cancer Institute | Soluble two domain cd2 protein |
ES2062519T5 (es) | 1989-03-21 | 2003-07-16 | Immune Response Corp Inc | Vacunacion y metodos contra enfermedades originadas a partir de respuestas patogenicas mediante poblaciones especificas de linfocitos t. |
DK0479909T3 (da) | 1989-06-29 | 1997-04-07 | Medarex Inc | Bispecifikke reagenser til AIDS-behandling |
JP3072330B2 (ja) | 1989-07-19 | 2000-07-31 | ジ・イミューン・レスポンス・コーポレーション | 自己免疫疾患および悪性疾患の治療のためのt細胞リセプターペプチド |
US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
US5208020A (en) | 1989-10-25 | 1993-05-04 | Immunogen Inc. | Cytotoxic agents comprising maytansinoids and their therapeutic use |
US5229275A (en) | 1990-04-26 | 1993-07-20 | Akzo N.V. | In-vitro method for producing antigen-specific human monoclonal antibodies |
US5571894A (en) | 1991-02-05 | 1996-11-05 | Ciba-Geigy Corporation | Recombinant antibodies specific for a growth factor receptor |
CA2102511A1 (en) | 1991-05-14 | 1992-11-15 | Paul J. Higgins | Heteroconjugate antibodies for treatment of hiv infection |
ATE255131T1 (de) | 1991-06-14 | 2003-12-15 | Genentech Inc | Humanisierter heregulin antikörper |
MX9204374A (es) * | 1991-07-25 | 1993-03-01 | Idec Pharma Corp | Anticuerpo recombinante y metodo para su produccion. |
US5565332A (en) | 1991-09-23 | 1996-10-15 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
US5587458A (en) | 1991-10-07 | 1996-12-24 | Aronex Pharmaceuticals, Inc. | Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof |
WO1993008829A1 (en) | 1991-11-04 | 1993-05-13 | The Regents Of The University Of California | Compositions that mediate killing of hiv-infected cells |
EP1136556B1 (en) | 1991-11-25 | 2005-06-08 | Enzon, Inc. | Method of producing multivalent antigen-binding proteins |
WO1993016185A2 (en) | 1992-02-06 | 1993-08-19 | Creative Biomolecules, Inc. | Biosynthetic binding protein for cancer marker |
CA2128862C (en) | 1992-02-11 | 2008-05-20 | Jonathan G. Seidman | Homogenotization of gene-targeting events |
US5573905A (en) | 1992-03-30 | 1996-11-12 | The Scripps Research Institute | Encoded combinatorial chemical libraries |
DE69322860T2 (de) | 1992-04-03 | 1999-07-01 | Genentech Inc | Antikörper gegen alpha v beta 3 integrin |
ZA932522B (en) | 1992-04-10 | 1993-12-20 | Res Dev Foundation | Immunotoxins directed against c-erbB-2(HER/neu) related surface antigens |
CA2134773A1 (en) | 1992-06-04 | 1993-12-09 | Robert J. Debs | Methods and compositions for in vivo gene therapy |
DE69308573T2 (de) | 1992-08-17 | 1997-08-07 | Genentech Inc | Bispezifische immunoadhesine |
US5736137A (en) * | 1992-11-13 | 1998-04-07 | Idec Pharmaceuticals Corporation | Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma |
US7744877B2 (en) * | 1992-11-13 | 2010-06-29 | Biogen Idec Inc. | Expression and use of anti-CD20 Antibodies |
PL174494B1 (pl) | 1992-11-13 | 1998-08-31 | Idec Pharma Corp | Kompozycja farmaceutyczna do leczenia chłoniaka z limfocytów B i sposób wytwarzania kompozycji farmaceutycznej do leczenia chłoniaka z limfocytów B |
US5417972A (en) | 1993-08-02 | 1995-05-23 | The Board Of Trustees Of The Leland Stanford Junior University | Method of killing B-cells in a complement independent and an ADCC independent manner using antibodies which specifically bind CDIM |
US5595721A (en) * | 1993-09-16 | 1997-01-21 | Coulter Pharmaceutical, Inc. | Radioimmunotherapy of lymphoma using anti-CD20 |
EP0771208B1 (en) * | 1994-08-12 | 2005-10-19 | Immunomedics, Inc. | Immunoconjugates and humanized antibodies specific for b-cell lymphoma and leukemia cells |
US5910486A (en) | 1994-09-06 | 1999-06-08 | Uab Research Foundation | Methods for modulating protein function in cells using, intracellular antibody homologues |
US6214388B1 (en) | 1994-11-09 | 2001-04-10 | The Regents Of The University Of California | Immunoliposomes that optimize internalization into target cells |
US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
US5641870A (en) | 1995-04-20 | 1997-06-24 | Genentech, Inc. | Low pH hydrophobic interaction chromatography for antibody purification |
US5739277A (en) | 1995-04-14 | 1998-04-14 | Genentech Inc. | Altered polypeptides with increased half-life |
US6267958B1 (en) | 1995-07-27 | 2001-07-31 | Genentech, Inc. | Protein formulation |
GB9603256D0 (en) | 1996-02-16 | 1996-04-17 | Wellcome Found | Antibodies |
US20010056066A1 (en) * | 1996-07-26 | 2001-12-27 | Smithkline Beecham Corporation | Method of treating immune cell mediated systemic diseases |
WO1998026086A1 (en) * | 1996-12-11 | 1998-06-18 | University Of Florida | Novel methods and compositions for treatment of autoimmune diseases |
US6306393B1 (en) | 1997-03-24 | 2001-10-23 | Immunomedics, Inc. | Immunotherapy of B-cell malignancies using anti-CD22 antibodies |
CA2292730C (en) | 1997-06-13 | 2008-09-16 | Genentech, Inc. | Stabilized antibody formulation |
US6171586B1 (en) | 1997-06-13 | 2001-01-09 | Genentech, Inc. | Antibody formulation |
ATE296315T1 (de) | 1997-06-24 | 2005-06-15 | Genentech Inc | Galactosylierte glykoproteine enthaltende zusammensetzungen und verfahren zur deren herstellung |
AU8296098A (en) | 1997-07-08 | 1999-02-08 | Board Of Regents, The University Of Texas System | Compositions and methods for homoconjugates of antibodies which induce growth arrest or apoptosis of tumor cells |
AU759779B2 (en) | 1997-10-31 | 2003-05-01 | Genentech Inc. | Methods and compositions comprising glycoprotein glycoforms |
US6528624B1 (en) * | 1998-04-02 | 2003-03-04 | Genentech, Inc. | Polypeptide variants |
CA2323757C (en) | 1998-04-02 | 2011-08-02 | Genentech, Inc. | Antibody variants and fragments thereof |
US6242195B1 (en) | 1998-04-02 | 2001-06-05 | Genentech, Inc. | Methods for determining binding of an analyte to a receptor |
US6194551B1 (en) * | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
ATE458007T1 (de) | 1998-04-20 | 2010-03-15 | Glycart Biotechnology Ag | Glykosylierungs-engineering von antikörpern zur verbesserung der antikörperabhängigen zellvermittelten zytotoxizität |
GB9811969D0 (en) | 1998-06-03 | 1998-07-29 | Celltech Therapeutics Ltd | Chemical compounds |
CA2340091C (en) | 1998-08-11 | 2013-02-05 | Idec Pharmaceuticals Corporation | Combination therapies for b-cell lymphomas comprising administration of anti-cd20 antibody |
GB9821061D0 (en) | 1998-09-28 | 1998-11-18 | Celltech Therapeutics Ltd | Chemical compounds |
US6224866B1 (en) | 1998-10-07 | 2001-05-01 | Biocrystal Ltd. | Immunotherapy of B cell involvement in progression of solid, nonlymphoid tumors |
CA2350064C (en) * | 1998-11-09 | 2012-05-08 | Idec Pharmaceuticals Corporation | Chimeric anti-cd20 antibody treatment of patients receiving bmt or pbsc transplants |
DE69942727D1 (de) | 1998-11-09 | 2010-10-14 | Biogen Idec Inc | Chimärer anti-CD20 Antikörper, Rituxan, zur Verwendung in der Behandlung der chronischen lymphatischen Leukemie |
GB9826174D0 (en) | 1998-11-30 | 1999-01-20 | Celltech Therapeutics Ltd | Chemical compounds |
GB9828074D0 (en) | 1998-12-18 | 1999-02-17 | Glaxo Group Ltd | Therapeutically useful compounds |
US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
EP2386574A3 (en) | 1999-01-15 | 2012-06-27 | Genentech, Inc. | Polypeptide variants with altered effector function |
US6897044B1 (en) | 1999-01-28 | 2005-05-24 | Biogen Idec, Inc. | Production of tetravalent antibodies |
EP1035172A3 (en) * | 1999-03-12 | 2002-11-27 | Fuji Photo Film Co., Ltd. | Azomethine compound and oily magenta ink |
EP3031917A1 (en) * | 1999-04-09 | 2016-06-15 | Kyowa Hakko Kirin Co., Ltd. | Method for controlling the activity of immunologically functional molecule |
EP1637160A3 (en) * | 1999-05-07 | 2006-05-03 | Genentech, Inc. | Treatment of autoimmune diseases with antagonists which bind to B cell surface markers |
DE05075555T1 (de) | 1999-06-09 | 2007-02-08 | Immunomedics, Inc. | Immuntherapie von Autoimmunerkrankungen durch die Verwendung von B-Zell-spezifischen Antikörpern |
ITMI991299A1 (it) | 1999-06-11 | 2000-12-11 | Consiglio Nazionale Ricerche | Uso di anticorpi contro antigeni di superficie per il trattamento della malattia trapianto contro ospite |
DE19930748C2 (de) * | 1999-07-02 | 2001-05-17 | Infineon Technologies Ag | Verfahren zur Herstellung von EEPROM- und DRAM-Grabenspeicherzellbereichen auf einem Chip |
MXPA02000419A (es) | 1999-07-12 | 2004-09-10 | Genentech Inc | Bloqueo de la respuesta inmune a un antigeno extrano utilizando un antagonista que se enlaza a cd20. |
US6451284B1 (en) | 1999-08-11 | 2002-09-17 | Idec Pharmaceuticals Corporation | Clinical parameters for determining hematologic toxicity prior to radioimmunotheraphy |
US8557244B1 (en) | 1999-08-11 | 2013-10-15 | Biogen Idec Inc. | Treatment of aggressive non-Hodgkins lymphoma with anti-CD20 antibody |
CA2378646A1 (en) | 1999-08-11 | 2001-02-15 | Idec Pharmaceuticals Corporation | Treatment of patients having non-hodgkins lymphoma with bone marrow involvement with anti-cd20 antibodies |
WO2001013945A1 (en) | 1999-08-23 | 2001-03-01 | Biocrystal Ltd. | Methods and compositions for immunotherapy of b cell involvement in promotion of a disease condition comprising multiple sclerosis |
CA2388245C (en) | 1999-10-19 | 2012-01-10 | Tatsuya Ogawa | The use of serum-free adapted rat cells for producing heterologous polypeptides |
IL149500A0 (en) | 1999-11-08 | 2002-11-10 | Idec Pharma Corp | Treatment of b cell malignancies using anti-cd40l antibodies in combination with anti-cd20 antibodies and/or chemotherapeutics and radiotherapy |
US20020006404A1 (en) | 1999-11-08 | 2002-01-17 | Idec Pharmaceuticals Corporation | Treatment of cell malignancies using combination of B cell depleting antibody and immune modulating antibody related applications |
WO2001062905A2 (en) | 2000-02-25 | 2001-08-30 | Immunex Corporation | Integrin antagonists |
JP2003528155A (ja) * | 2000-03-24 | 2003-09-24 | カイロン コーポレイション | Cd20に対する抗体とインターロイキン−2との組み合わせを用いる非ホジキンリンパ腫の治療方法 |
US20030185796A1 (en) | 2000-03-24 | 2003-10-02 | Chiron Corporation | Methods of therapy for non-hodgkin's lymphoma |
CN1441677A (zh) * | 2000-03-31 | 2003-09-10 | Idec药物公司 | 抗细胞因子抗体或拮抗剂与抗-cd20在b细胞淋巴瘤治疗中的联合应用 |
IL151853A0 (en) | 2000-04-11 | 2003-04-10 | Genentech Inc | Multivalent antibodies and uses therefor |
ATE375330T1 (de) | 2000-04-17 | 2007-10-15 | Ucb Pharma Sa | Enamin-derivate als zell-adhäsionsmoleküle |
CN1437478A (zh) | 2000-04-25 | 2003-08-20 | Idec药物公司 | 瑞图希单抗的鞘内施用,用于中枢神经系统淋巴瘤的治疗 |
WO2001097858A2 (en) | 2000-06-20 | 2001-12-27 | Idec Pharmaceuticals Corporation | Cold anti-cd20 antibody/radiolabeled anti-cd22 antibody combination |
WO2001097843A2 (en) * | 2000-06-22 | 2001-12-27 | University Of Iowa Research Foundation | Methods for enhancing antibody-induced cell lysis and treating cancer |
US6960597B2 (en) | 2000-06-30 | 2005-11-01 | Orth-Mcneil Pharmaceutical, Inc. | Aza-bridged-bicyclic amino acid derivatives as α4 integrin antagonists |
KR20030031957A (ko) | 2000-07-12 | 2003-04-23 | 아이덱 파마슈티칼즈 코포레이션 | B 세포 고갈 항체 및 면역 조절 항체 관련 적용의 조합을이용한 b 세포 악성종양의 치료 |
HU228914B1 (hu) | 2000-08-18 | 2013-06-28 | Ajinomoto Kk | Fenilalanin-származékok |
EP1311549A2 (en) * | 2000-08-22 | 2003-05-21 | Micromet AG | Composition for the elimination of autoreactive b-cells |
CN1592645A (zh) * | 2000-09-18 | 2005-03-09 | 拜奥根Idec公司 | 使用b细胞耗尽/免疫调节抗体组合治疗自身免疫病的联合疗法 |
DE60124573T2 (de) | 2000-09-29 | 2007-06-21 | Ajinomoto Co., Inc. | Neue phenylalanin-derivate |
US7064191B2 (en) | 2000-10-06 | 2006-06-20 | Kyowa Hakko Kogyo Co., Ltd. | Process for purifying antibody |
US6946292B2 (en) | 2000-10-06 | 2005-09-20 | Kyowa Hakko Kogyo Co., Ltd. | Cells producing antibody compositions with increased antibody dependent cytotoxic activity |
WO2002034790A1 (en) | 2000-10-20 | 2002-05-02 | Idec Pharmaceuticals Corporation | Variant igg3 rituxan r and therapeutic use thereof |
KR20030074693A (ko) | 2000-12-28 | 2003-09-19 | 알투스 바이올로직스 인코포레이티드 | 전항체 및 이의 단편의 결정과 이의 제조 및 사용 방법 |
CN1268394C (zh) | 2001-01-17 | 2006-08-09 | 特鲁比昂药品公司 | 结合域-免疫球蛋白融合蛋白 |
EP1373321A2 (en) | 2001-01-29 | 2004-01-02 | Idec Pharmaceuticals Corporation | Modified antibodies and methods of use |
WO2002096948A2 (en) | 2001-01-29 | 2002-12-05 | Idec Pharmaceuticals Corporation | Engineered tetravalent antibodies and methods of use |
US20030103971A1 (en) | 2001-11-09 | 2003-06-05 | Kandasamy Hariharan | Immunoregulatory antibodies and uses thereof |
IL157946A0 (en) * | 2001-04-02 | 2004-03-28 | Genentech Inc | Combination therapy |
WO2002079255A1 (en) | 2001-04-02 | 2002-10-10 | Idec Pharmaceuticals Corporation | RECOMBINANT ANTIBODIES COEXPRESSED WITH GnTIII |
WO2003061694A1 (en) | 2001-05-10 | 2003-07-31 | Seattle Genetics, Inc. | Immunosuppression of the humoral immune response by anti-cd20 antibodies |
WO2002102312A2 (en) | 2001-06-14 | 2002-12-27 | Intermune, Inc. | Combination therapy of gamma-interferon and b cell specific antibodies |
US7321026B2 (en) | 2001-06-27 | 2008-01-22 | Skytech Technology Limited | Framework-patched immunoglobulins |
WO2003010135A1 (fr) | 2001-07-26 | 2003-02-06 | Ajinomoto Co., Inc. | Nouveaux derives de l'acide phenylpropionique |
NZ571596A (en) | 2001-08-03 | 2010-11-26 | Glycart Biotechnology Ag | Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity |
EP2131198B1 (en) | 2001-09-20 | 2013-03-27 | Board of Regents, The University of Texas System | Measuring circulating therapeutic antibody, antigen and antigen/antibody complexes using ELISA assays |
EP1443961B1 (en) | 2001-10-25 | 2009-05-06 | Genentech, Inc. | Glycoprotein compositions |
AU2002362098A1 (en) | 2001-12-07 | 2003-06-23 | Chiron Corporation | Methods of therapy for non-hodgkin's lymphoma |
AU2002354224A1 (en) | 2001-12-13 | 2003-07-09 | Ajinomoto Co., Inc. | Novel phenylalanine derivative |
US20040093621A1 (en) * | 2001-12-25 | 2004-05-13 | Kyowa Hakko Kogyo Co., Ltd | Antibody composition which specifically binds to CD20 |
CN100522999C (zh) * | 2002-02-14 | 2009-08-05 | 免疫医疗公司 | 抗cd20抗体及其融合蛋白和使用方法 |
ATE464299T1 (de) | 2002-02-20 | 2010-04-15 | Ajinomoto Kk | Neues phenylalaninderivat |
US20030180292A1 (en) * | 2002-03-14 | 2003-09-25 | Idec Pharmaceuticals | Treatment of B cell malignancies using anti-CD40L antibodies in combination with anti-CD20 antibodies and/or chemotherapeutics and radiotherapy |
AU2003236018A1 (en) * | 2002-04-09 | 2003-10-20 | Kyowa Hakko Kirin Co., Ltd. | METHOD OF ENHANCING ACTIVITY OF ANTIBODY COMPOSITION OF BINDING TO FcGamma RECEPTOR IIIa |
US7691568B2 (en) | 2002-04-09 | 2010-04-06 | Kyowa Hakko Kirin Co., Ltd | Antibody composition-containing medicament |
US20040132140A1 (en) | 2002-04-09 | 2004-07-08 | Kyowa Hakko Kogyo Co., Ltd. | Production process for antibody composition |
WO2003085102A1 (fr) | 2002-04-09 | 2003-10-16 | Kyowa Hakko Kogyo Co., Ltd. | Cellule avec inhibition ou suppression de l'activite de la proteine participant au transport du gdp-fucose |
US20050031613A1 (en) | 2002-04-09 | 2005-02-10 | Kazuyasu Nakamura | Therapeutic agent for patients having human FcgammaRIIIa |
US20040110704A1 (en) | 2002-04-09 | 2004-06-10 | Kyowa Hakko Kogyo Co., Ltd. | Cells of which genome is modified |
AU2003235256A1 (en) | 2002-04-19 | 2003-11-03 | Kyowa Hakko Kogyo Co., Ltd. | Phenylalanine derivative |
US20030219818A1 (en) * | 2002-05-10 | 2003-11-27 | Bohen Sean P. | Methods and compositions for determining neoplastic disease responsiveness to antibody therapy |
US20050180972A1 (en) | 2002-07-31 | 2005-08-18 | Wahl Alan F. | Anti-CD20 antibody-drug conjugates for the treatment of cancer and immune disorders |
AU2003279225B2 (en) * | 2002-10-08 | 2008-10-09 | Exxonmobil Research And Engineering Company | Heavy hydrocarbon composition with utility as a heavy lubricant base stock |
AU2003301445A1 (en) | 2002-10-17 | 2004-05-04 | Genmab A/S | Human monoclonal antibodies against cd20 |
ES2633311T3 (es) | 2002-12-16 | 2017-09-20 | Genentech, Inc. | Variantes de inmunoglobulina y usos de las mismas |
US7534427B2 (en) | 2002-12-31 | 2009-05-19 | Immunomedics, Inc. | Immunotherapy of B cell malignancies and autoimmune diseases using unconjugated antibodies and conjugated antibodies and antibody combinations and fusion proteins |
PL1613350T3 (pl) | 2003-04-09 | 2009-08-31 | Genentech Inc | Leczenie choroby autoimmunologicznej u pacjenta z nieodpowiednią odpowiedzią na leczenie inhibitorem TNFα |
JP5416338B2 (ja) | 2003-05-09 | 2014-02-12 | デューク ユニバーシティ | Cd20特異的抗体およびその使用方法 |
AR044388A1 (es) | 2003-05-20 | 2005-09-07 | Applied Molecular Evolution | Moleculas de union a cd20 |
BRPI0411276A (pt) | 2003-06-05 | 2006-08-01 | Genentech Inc | métodos de esgotamento de células b, método de tratamento de neoplasma de células b ou malignidade, método de alìvio de disfunção autoimunológica regulada por células b, composição e artigo industrializado |
CN1860367B (zh) * | 2003-07-29 | 2010-05-26 | 健泰科生物技术公司 | 人抗cd20抗体的测定法及其用途 |
EP1651663B1 (en) | 2003-08-08 | 2017-05-17 | Immunomedics, Inc. | Bispecific antibodies for inducing apoptosis of tumor and diseased cells |
US8147832B2 (en) | 2003-08-14 | 2012-04-03 | Merck Patent Gmbh | CD20-binding polypeptide compositions and methods |
JP2007504138A (ja) | 2003-08-29 | 2007-03-01 | ジェネンテック・インコーポレーテッド | 眼疾患の治療法 |
US20080241884A1 (en) | 2003-10-08 | 2008-10-02 | Kenya Shitara | Fused Protein Composition |
AU2004280065A1 (en) | 2003-10-09 | 2005-04-21 | Kyowa Hakko Kirin Co., Ltd. | Process for producing antibody composition by using RNA inhibiting the function of alpha1,6-fucosyltransferase |
RU2006142857A (ru) * | 2004-05-05 | 2008-06-10 | Дженентек, Инк. (Us) | Профилактика аутоиммунного заболевания |
TW201014605A (en) * | 2008-09-16 | 2010-04-16 | Genentech Inc | Methods for treating progressive multiple sclerosis |
-
2005
- 2005-06-02 KR KR1020137020073A patent/KR20130099228A/ko not_active Application Discontinuation
- 2005-06-02 ZA ZA200610158A patent/ZA200610158B/en unknown
- 2005-06-02 RU RU2006147253/14A patent/RU2384345C2/ru active
- 2005-06-02 TW TW094118185A patent/TWI433682B/zh active
- 2005-06-02 CN CN2011104417566A patent/CN102512675A/zh active Pending
- 2005-06-02 EP EP16179276.7A patent/EP3130349A1/en not_active Withdrawn
- 2005-06-02 AU AU2005249566A patent/AU2005249566B2/en active Active
- 2005-06-02 MY MYPI20052531A patent/MY194883A/en unknown
- 2005-06-02 KR KR1020157020875A patent/KR20150092374A/ko not_active Application Discontinuation
- 2005-06-02 KR KR1020067025348A patent/KR20070029733A/ko not_active Application Discontinuation
- 2005-06-02 US US11/143,386 patent/US20060051345A1/en not_active Abandoned
- 2005-06-02 BR BRPI0510915-9A patent/BRPI0510915A/pt not_active Application Discontinuation
- 2005-06-02 WO PCT/US2005/019641 patent/WO2005117978A2/en active Application Filing
- 2005-06-02 CN CN201610550354.2A patent/CN106075435A/zh active Pending
- 2005-06-02 NZ NZ604082A patent/NZ604082A/en unknown
- 2005-06-02 MX MXPA06014069A patent/MXPA06014069A/es active IP Right Grant
- 2005-06-02 EP EP05756597A patent/EP1753455A2/en not_active Ceased
- 2005-06-02 SG SG2012050688A patent/SG183012A1/en unknown
- 2005-06-02 TW TW102143567A patent/TW201422238A/zh unknown
- 2005-06-02 JP JP2007515637A patent/JP2008501712A/ja active Pending
- 2005-06-02 AR ARP050102270A patent/AR049200A1/es unknown
- 2005-06-02 SV SV2005002132A patent/SV2006002132A/es unknown
- 2005-06-02 CN CNA2005800266023A patent/CN1993143A/zh active Pending
- 2005-06-02 CA CA002566979A patent/CA2566979A1/en not_active Abandoned
-
2006
- 2006-11-09 IL IL179139A patent/IL179139A/en active IP Right Grant
-
2007
- 2007-01-03 NO NO20070052A patent/NO20070052L/no not_active Application Discontinuation
-
2010
- 2010-02-26 US US12/713,366 patent/US20100233121A1/en not_active Abandoned
-
2012
- 2012-04-05 US US13/440,916 patent/US20120199516A1/en not_active Abandoned
- 2012-04-19 IL IL219285A patent/IL219285A/en active IP Right Grant
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NZ604082A (en) | Method for treating multiple sclerosis | |
CL2013003373A1 (es) | Proteina de union al antigeno de maduración de linfocitos b (bcma); composicion farmacéutica que comprende la proteína; uso para preparar un medicamento util para tratar mieloma multiple o (mm) leucemia linfocitica cronica (cll). | |
RS54452B1 (en) | INGREDIENTS AND PROCEDURES FOR DIAGNOSIS AND TREATMENT OF CANCER | |
NZ585559A (en) | Humanized antibodies against tl1a | |
NZ568403A (en) | CD20-specific antibodies and methods of employing same | |
DK1684869T3 (da) | Fremgangsmåde til terapi af B-celle-relaterede cancersygdomme | |
RS52889B (sr) | Terapijsko humano anti-il-1r1 monoklonsko antitelo | |
JP2020037555A5 (pt) | ||
WO2006041680A3 (en) | Method for treating vasculitis | |
CA2494008A1 (en) | Anti-myelin associated glycoprotein (mag) antibodies | |
JP2015535828A5 (pt) | ||
JP2006512899A5 (pt) | ||
CO5631451A2 (es) | Anticuerpo especifico para cd22 humano y composicion farmaceutica derivada | |
RS52919B (en) | SCLEROSTINE BINDING AGENTS | |
JP2016531915A5 (pt) | ||
JP2016538318A5 (pt) | ||
JP2018507220A5 (pt) | ||
GEP20074222B (en) | Antibodies to cd40 | |
RU2008141171A (ru) | Анти-тат226 антитела и иммуноконъюгаты | |
NZ705848A (en) | Anti-cd38 antibodies | |
MX2020008445A (es) | Metodos para tratar el cancer con anticuerpos anti-pd-1. | |
NZ631405A (en) | Combination of anti-kir antibodies and anti-pd-1 antibodies to treat cancer | |
NZ575245A (en) | Targeted binding agents directed to pdgfr-alpha and uses thereof | |
NZ599196A (en) | Human anti-ngf neutralizing antibodies as selective ngf pathway inhibitors | |
SI2579894T1 (en) | CGRP PROTITELESA |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
ERR | Error or correction |
Free format text: THE FILED DATE HAS BEEN CORRECTED TO 02/06/2005; THE PATENT COMPLETE SPECIFICATION DATE HAS BEEN CORRECTED TO 02/05/2005 Effective date: 20130104 |
|
ERR | Error or correction |
Free format text: THE PATENT COMPLETE SPECIFICATION DATE HAS BEEN CORRECTED TO 02/06/2005 Effective date: 20140721 |
|
S23 | Proceedings under section 23: mention of inventor as such in patent |
Free format text: INVENTOR FROHNA, PAUL A ADDED Effective date: 20140731 |
|
PSEA | Patent sealed | ||
RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 6 YEARS UNTIL 02 JUN 2015 BY AJ PARK Effective date: 20150211 |
|
RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 02 JUN 2016 BY THOMSON REUTERS Effective date: 20150514 |
|
RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 02 JUN 2017 BY THOMSON REUTERS Effective date: 20160512 |
|
RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 02 JUN 2018 BY THOMSON REUTERS Effective date: 20170527 |
|
RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 02 JUN 2019 BY THOMSON REUTERS Effective date: 20180509 |
|
RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 02 JUN 2020 BY THOMSON REUTERS Effective date: 20190516 |
|
RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 02 JUN 2021 BY THOMSON REUTERS Effective date: 20200517 |
|
RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 02 JUN 2022 BY THOMSON REUTERS Effective date: 20210505 |
|
RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 02 JUN 2023 BY THOMSON REUTERS Effective date: 20220503 |
|
RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 02 JUN 2024 BY THOMSON REUTERS Effective date: 20230501 |